Blueprint Medicines Corp Stock Performance
| BPMC Stock | USD 104.96 1.68 1.58% |
On a scale of 0 to 100, Blueprint Medicines holds a performance score of 6. The firm shows a Beta (market volatility) of 2.43, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Blueprint Medicines will likely underperform. Please check Blueprint Medicines' expected short fall, day median price, and the relationship between the potential upside and accumulation distribution , to make a quick decision on whether Blueprint Medicines' price patterns will revert.
Risk-Adjusted Performance
6 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Blueprint Medicines Corp are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of rather unsteady primary indicators, Blueprint Medicines exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (1.58) | Five Day Return (3.85) | Year To Date Return 15.25 | Ten Year Return 456.23 | All Time Return 456.23 |
1 | Disposition of 621 shares by Christopher Murray of Blueprint Medicines at 93.65 subject to Rule 16b-3 | 03/04/2024 |
2 | Moderna Soars 8.7 percent Is Further Upside Left in the Stock | 03/12/2024 |
3 | Disposition of 6223 shares by Lee Philina of Blueprint Medicines at 90.55 subject to Rule 16b-3 | 03/18/2024 |
4 | Disposition of 10000 shares by Jeffrey Albers of Blueprint Medicines at 15.01 subject to Rule 16b-3 | 03/20/2024 |
5 | Sustained Product Demand Likely to Aid BDs Q2 Earnings | 04/29/2024 |
6 | Will Apellis Pharmaceuticals, Inc. Report Negative Earnings Next Week What You Should Know | 04/30/2024 |
7 | 05/02/2024 |
8 | Blueprint Medicines Corp Earnings Call Transcript Highlights Surpassing ... | 05/03/2024 |
9 | Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635 | 05/06/2024 |
10 | Acquisition by Michael Landsittel of 1818 shares of Blueprint Medicines at 8.8 subject to Rule 16b-3 | 05/08/2024 |
11 | Blueprint Medicines started at buy by Stephens, citing Ayvakit franchise | 05/14/2024 |
12 | Blueprint Medicines Co. to Post Q2 2024 Earnings of Per Share, Zacks Research Forecasts - MarketBeat | 05/16/2024 |
| Begin Period Cash Flow | 119.7 M |
Blueprint |
Blueprint Medicines Relative Risk vs. Return Landscape
If you would invest 9,125 in Blueprint Medicines Corp on February 19, 2024 and sell it today you would earn a total of 1,371 from holding Blueprint Medicines Corp or generate 15.02% return on investment over 90 days. Blueprint Medicines Corp is currently generating 0.2628% in daily expected returns and assumes 3.0148% risk (volatility on return distribution) over the 90 days horizon. In different words, 26% of stocks are less volatile than Blueprint, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Blueprint Medicines Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Blueprint Medicines' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Blueprint Medicines Corp, and traders can use it to determine the average amount a Blueprint Medicines' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0872
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | BPMC | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.01 actual daily | 26 74% of assets are more volatile |
Expected Return
| 0.26 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 6 94% of assets perform better |
Based on monthly moving average Blueprint Medicines is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Blueprint Medicines by adding it to a well-diversified portfolio.
Blueprint Medicines Fundamentals Growth
Blueprint Stock prices reflect investors' perceptions of the future prospects and financial health of Blueprint Medicines, and Blueprint Medicines fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Blueprint Stock performance.
| Return On Equity | -0.8 | ||||
| Return On Asset | -0.24 | ||||
| Profit Margin | (1.02) % | ||||
| Operating Margin | (0.82) % | ||||
| Current Valuation | 6.52 B | ||||
| Shares Outstanding | 62.62 M | ||||
| Price To Earning | 7.93 X | ||||
| Price To Book | 40.90 X | ||||
| Price To Sales | 21.42 X | ||||
| Revenue | 249.38 M | ||||
| Gross Profit | 177.28 M | ||||
| EBITDA | (474.61 M) | ||||
| Net Income | (506.98 M) | ||||
| Cash And Equivalents | 853.11 M | ||||
| Cash Per Share | 14.28 X | ||||
| Total Debt | 774.12 M | ||||
| Debt To Equity | 0.14 % | ||||
| Current Ratio | 6.00 X | ||||
| Book Value Per Share | 4.96 X | ||||
| Cash Flow From Operations | (436.85 M) | ||||
| Earnings Per Share | (4.82) X | ||||
| Market Capitalization | 6.57 B | ||||
| Total Asset | 1.05 B | ||||
| Retained Earnings | (2.34 B) | ||||
| Working Capital | 593.47 M | ||||
| Current Asset | 170.42 M | ||||
| Current Liabilities | 18.64 M | ||||
About Blueprint Medicines Performance
To evaluate Blueprint Medicines Corp Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Blueprint Medicines generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Blueprint Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Blueprint Medicines Corp market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Blueprint's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 316.68 | 300.85 | |
| Return On Tangible Assets | (0.48) | (0.51) | |
| Return On Capital Employed | (0.58) | (0.61) | |
| Return On Assets | (0.48) | (0.51) | |
| Return On Equity | (3.88) | (3.69) |
Things to note about Blueprint Medicines Corp performance evaluation
Checking the ongoing alerts about Blueprint Medicines for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Blueprint Medicines Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Blueprint Medicines had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 249.38 M. Net Loss for the year was (506.98 M) with profit before overhead, payroll, taxes, and interest of 177.28 M. | |
| Blueprint Medicines Corp currently holds about 853.11 M in cash with (436.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 14.28. | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Blueprint Medicines Co. to Post Q2 2024 Earnings of Per Share, Zacks Research Forecasts - MarketBeat |
- Analyzing Blueprint Medicines' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Blueprint Medicines' stock is overvalued or undervalued compared to its peers.
- Examining Blueprint Medicines' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Blueprint Medicines' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Blueprint Medicines' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Blueprint Medicines' stock. These opinions can provide insight into Blueprint Medicines' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Blueprint Medicines Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Complementary Tools for Blueprint Stock analysis
When running Blueprint Medicines' price analysis, check to measure Blueprint Medicines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Blueprint Medicines is operating at the current time. Most of Blueprint Medicines' value examination focuses on studying past and present price action to predict the probability of Blueprint Medicines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Blueprint Medicines' price. Additionally, you may evaluate how the addition of Blueprint Medicines to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
Is Blueprint Medicines' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Blueprint Medicines. If investors know Blueprint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Blueprint Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.82) | Revenue Per Share 4.632 | Quarterly Revenue Growth 0.519 | Return On Assets (0.24) | Return On Equity (0.80) |
The market value of Blueprint Medicines Corp is measured differently than its book value, which is the value of Blueprint that is recorded on the company's balance sheet. Investors also form their own opinion of Blueprint Medicines' value that differs from its market value or its book value, called intrinsic value, which is Blueprint Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Blueprint Medicines' market value can be influenced by many factors that don't directly affect Blueprint Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Blueprint Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Blueprint Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Blueprint Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.